#52026XC02805EU Marketing Authorisations for Medicinal Products in April 2026
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This notice lists EU decisions granting marketing authorisations for medicinal products between 1 April and 30 April 2026. The authorised products include vaccines, cancer medicines, biosimilars, immunology treatments, neurological medicines, and other therapies from companies such as Merck, Moderna, Ipsen, Novartis, Organon, and Gedeon Richter. The notice matters mainly for pharmaceutical companies, healthcare providers, wholesalers, and compliance teams tracking which centrally authorised medicines can be placed on the EU market. It is an administrative publication, not a broader policy change.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Lists new EU marketing authorisations granted for medicinal products in April 2026
- Includes authorisations for products such as Enflonsia, mCOMBRIAX, Ojemda, Fubelv, Palsonify, Poherdy, Rhapsido, Onerji, Tuyory, Xolremdi, and Zandoriah
- Provides register numbers, product forms, authorisation holders, decision dates, and notification dates